about
Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients."Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.Modulation of GemOx chemotherapy according to CIRS in elderly patients with advanced pancreatic cancer.Multidisciplinary management of hepatocellular carcinoma in clinical practice.Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen.Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer.Advanced colon cancer: staging and prognosis by CEA test.Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic diseaseWorse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)Dose-dense nonpegylated liposomal Doxorubicin and docetaxel combination in breast cancer: dose-finding studyPlasma Proteomic Profiling in Hereditary Breast Cancer Reveals a BRCA1-Specific Signature: Diagnostic and Functional ImplicationsReducing breast cancer incidence in familial breast cancer: overlooking the present panorama.Prophylactic options in patients with 5-fluorouracil-associated cardiotoxicity.Axitinib after Sunitinib in Metastatic Renal Cancer: Preliminary Results from Italian "Real-World" SAX Study.New schedule of bevacizumab/paclitaxel as first-line therapy for metastatic HER2-negative breast cancer in a real-life setting.Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype.Triplet chemotherapy in patients with metastatic colorectal cancer: toward the best way to safely administer a highly active regimen in clinical practice.Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer.The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs.Tailoring the dosing schedule of nab-paclitaxel in metastatic breast cancer according to patient and disease characteristics: Recommendations from a panel of experts.Bone targeted therapy for preventing skeletal-related events in metastatic breast cancer.Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.Trifluoroibuprofen inhibits α-methylacyl coenzyme A racemase (AMACR/P504S), reduces cancer cell proliferation and inhibits in vivo tumor growth in aggressive prostate cancer models.Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines.Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models.Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro.Her2 crosstalks with TrkA in a subset of prostate cancer cells: rationale for a guided dual treatment.Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.In vitro and in vivo effects of bicalutamide on the expression of TrkA and P75 neurotrophin receptors in prostate carcinoma.Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro.Apoptosis induced by oxaliplatin in human colon cancer HCT15 cell line.Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy.Effectiveness and safety of intensive triplet chemotherapy plus bevacizumab, FIr-B/FOx, in young-elderly metastatic colorectal cancer patients.Evaluation of widely used models for predicting BRCA1 and BRCA2 mutations.Triplet schedule of weekly 5-fluorouracil and alternating irinotecan or oxaliplatin in advanced colorectal cancer: a dose-finding and phase II study.Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma.Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer.A six-gene signature predicting breast cancer lung metastasis.[Oxaliplatin: preclinical in vitro studies]
P50
Q30250038-E42F19A4-D1D5-4B70-A7C4-D7C948387F62Q30990540-85ACE2AB-8824-443C-96D3-802D8BC06B6EQ33397777-C929FE0F-600F-4B6C-8245-847C0A3F63E3Q33666679-91760378-67CE-434A-B127-EC06E9BFC92DQ33778129-EAE44790-3DC2-4466-99D7-828462790121Q34084450-F935AFB2-8FC0-48F9-A955-2E551A91E445Q34311425-6378A8D9-419B-4D56-A843-C30C9E5C4C9BQ34470974-5735B53E-7F64-4F7C-A8EE-7EFB61404CD8Q34622865-7C337532-EB3F-4A99-B9E8-1ED06773737CQ35057287-31AE6609-C65F-4768-8F3C-1C9D03978FBEQ35659498-8F845C2F-5D4E-42E3-92D5-E1908A325C28Q35848789-1D3A233B-5662-4B64-9AC1-0ECFF52C19FFQ36648933-E1CE794F-9702-4774-814B-2A2F1591F1E4Q37290050-D51B3A39-7042-47C6-BB74-85B56EAC7A00Q37321051-F6C38C2D-0C65-4E50-ACDF-DFAAC5D08052Q37401956-ECCCF685-9005-412F-85F8-331D0AA76154Q38018403-5C9B1CC4-B20F-4506-A597-B5BAE4F9112BQ38223782-6405D58C-7FFF-4234-BF94-9E7073AF0157Q38280407-7E9BC22D-4654-4BD6-AC14-0C3FF171FDC1Q38324305-94457317-13F9-447D-8F85-53ADC336BDDFQ38681957-DB163678-BB54-43E1-9D5A-1E0951C67F25Q38811394-E490A21F-8281-4423-9537-04E66A0033A0Q38848501-1D938ABD-4233-4146-A8A4-8FB81233D415Q39006588-3BAE6ED9-38E3-4424-88AF-7FFCDC3F38F5Q39067088-E275A879-6964-425B-919C-9CD17CF68998Q39434331-C41CD1ED-D525-4594-96C3-560284F64AADQ39831722-1B24A4A8-B5B4-43FA-BCFC-018DFDF20478Q39915300-D0D40130-1CA7-45D9-8B22-6A0F822B33BAQ39959978-D3BA0443-0053-4867-8783-A83A4D8B9A20Q40114375-40C3B439-5FDE-4CB8-A965-3CA66B6613EFQ40201277-AB5BC358-B54E-4B9A-B2A3-3DF0C40E54C0Q40579698-99A51324-CFF4-4044-A904-8FD9D5AAEBFAQ41044367-7454DABE-4E14-4911-A9EE-AAAC083C4523Q42870892-170C5D08-1AC4-411F-ABAB-D80A7F03C355Q43073772-D7CD4F45-8767-45D2-A177-55EDC77CFC3AQ43080891-897FD7E7-BBCA-4452-9E0B-29AEB8EE0F81Q43267010-5A009512-C128-4C17-B101-0820E33B2474Q43269934-C089A308-E8EE-415F-A08C-C2F8767E9244Q43729093-F974FD73-05CE-4CC3-853E-32F8E184E149Q43983030-10C1D633-BB12-4386-BFC9-52A2D0F86383
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Enrico Ricevuto
@ast
Enrico Ricevuto
@en
Enrico Ricevuto
@es
Enrico Ricevuto
@nl
Enrico Ricevuto
@sl
type
label
Enrico Ricevuto
@ast
Enrico Ricevuto
@en
Enrico Ricevuto
@es
Enrico Ricevuto
@nl
Enrico Ricevuto
@sl
prefLabel
Enrico Ricevuto
@ast
Enrico Ricevuto
@en
Enrico Ricevuto
@es
Enrico Ricevuto
@nl
Enrico Ricevuto
@sl
P106
P1153
6701828649
P21
P31
P496
0000-0001-5641-3187